Compare HUBB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBB | NTRA |
|---|---|---|
| Founded | 1888 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 28.0B |
| IPO Year | 2004 | 2015 |
| Metric | HUBB | NTRA |
|---|---|---|
| Price | $481.82 | $196.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $520.38 | $259.07 |
| AVG Volume (30 Days) | 532.6K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 15.10 | 0.65 |
| EPS | ★ 16.54 | N/A |
| Revenue | ★ $5,844,600,000.00 | $210,939,000.00 |
| Revenue This Year | $10.31 | $18.16 |
| Revenue Next Year | $5.43 | $20.00 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $299.43 | $125.38 |
| 52 Week High | $533.80 | $256.36 |
| Indicator | HUBB | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 44.22 |
| Support Level | $472.14 | $194.03 |
| Resistance Level | $505.77 | $204.34 |
| Average True Range (ATR) | 16.75 | 6.54 |
| MACD | 1.65 | 0.81 |
| Stochastic Oscillator | 37.47 | 51.11 |
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, in electrical substations, and in commercial and industrial buildings. The company's primary operations are in the United States, where around 90% of revenue is derived.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.